Drug
Fostemsavir clinical trials
Also written BMS-663068.
Includes 1 study of Fostemsavir tromethamine.
- studies test it
- 21
- open now
- 2
- in phase 3
- 2
- first study started
- 2011
Keep track of what changes. Save the fostemsavir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
21 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 5 |
| 2021 | 1 |
| 2022 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 16
- Phase 2
- 3
- Phase 3
- 2
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 3
ViiV Healthcare (18) · PENTA Foundation (1) · Orlando Immunology Center (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1)
Often tested with
Tested in the same studies.
Ritonavir (2) · VH3810109 (1) · Rosuvastatin (1) · Maraviroc (1) · Rifabutin (1) · Methadone (1) · Darunavir (1) · Etravirine (1)
Studies
Open first, then newest update. How each study uses fostemsavir is read from its arms, and is right about nine times in ten.
Testing it · 21
- A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentRecruitingPhase 3ViiV HealthcareNCT07393659Written as Fostemsavir
- Reducing Systemic Inflammation in People on Antiretroviral TherapyRecruitingPhase 2Centre hospitalier de l'Université de Montréal (CHUM)NCT07030920Written as Fostemsavir
- A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIVActive, not recruitingPhase 1ViiV HealthcareNCT07053384Written as Fostemsavir (FTR)
- Attachment Inhibitor Comparison in Heavily Treatment Experienced PatientsActive, not recruitingPhase 3ViiV HealthcareNCT02362503Written as BMS-663068
- Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral ResistanceActive, not recruitingPhase 1/2PENTA FoundationNCT04648280Written as Fostemsavir
- Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER StudyActive, not recruitingPhase 4Orlando Immunology CenterNCT05220358Written as Fostemsavir 600 MG [Rukobia]
- Low-dose Fostemsavir Extended Release Relative Bioavailability StudyCompletedPhase 1ViiV HealthcareNCT04757974Written as Fostemsavir 600 mg
- HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) InfectionsCompletedPhase 2ViiV HealthcareNCT01384734Written as BMS-663068 400 mg
- A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)CompletedPhase 1ViiV HealthcareNCT02674581Written as Oral BMS-663068 (pro-drug)
- Study on PharmacokineticsCompletedPhase 1ViiV HealthcareNCT02234882Written as BMS-663068
- A Open-label, Drug-Drug Interaction With Maraviroc (DDI)CompletedPhase 1ViiV HealthcareNCT02480894Written as BMS-663068
- Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy SubjectsCompletedPhase 1ViiV HealthcareNCT02467335Written as BMS-663068
- Drug-drug Interaction (DDI) RifabutinCompletedPhase 1ViiV HealthcareNCT02138084Written as BMS-663068
- Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release TabletCompletedPhase 1ViiV HealthcareNCT02508064Written as BMS-663068
- A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy SubjectsCompletedPhase 1ViiV HealthcareNCT02666053Written as BMS-663068
- A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/NaloxoneCompletedPhase 1ViiV HealthcareNCT02666001Written as BMS-663068
- DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)CompletedPhase 1ViiV HealthcareNCT02063360Written as BMS-663068
- A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)CompletedPhase 1ViiV HealthcareNCT02480881Written as BMS-663068
- Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529CompletedPhase 1ViiV HealthcareNCT02164045Written as BMS-663068
- Absolute Bioavailability of BMS-626529 After Oral and Intravenous DosingCompletedPhase 1ViiV HealthcareNCT02805556Written as BMS-663068
See all 21 studies that test fostemsavir →
Given in every arm · 2 — fostemsavir is usual care beside what is tested
- Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1CompletedPhase 2ViiV HealthcareNCT01009814Written as BMS-663068
- A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)CompletedPhase 1ViiV HealthcareNCT02277600Written as BMS-663068
Codes
What other systems call fostemsavir · ClinicalTrials.gg INT006176
- MeSH (NLM) C576364fostemsavirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 97IQ273H4LFOSTEMSAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 2380373One source FDA
- Wikidata Q17001240fostemsavirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175066FostemsavirOne source FDA
- DrugBank DB11796One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C576364 | fostemsavir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 97IQ273H4L | FOSTEMSAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2380373 | — | One source FDA |
| Wikidata | Q17001240 | fostemsavir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175066 | Fostemsavir | One source FDA |
| DrugBank | DB11796 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.